ChemoMetec (CHEMM) Q4 2025 earnings summary

Executive summary

• Revenue, EBITDA, EBITDA margin, profit before tax, and cash flow all increased year-over-year, reflecting strong overall performance.

• Q4 EBITDA margin was 50%, impacted by $12 million in restructuring costs; adjusted margin would be 56%.

• Successful integration of the OVCO acquisition, with operational functions centralized and R&D retained in Belgium.

Financial highlights

• Revenue growth was achieved across all product segments year-over-year.

• Q4 saw strong consumable sales, with nearly 30% growth at constant exchange rates.

• $12 million in restructuring costs were recognized, with $8 million in Q4.

• Staff headcount reduced from 184 to 170 by year-end, reflecting late-year restructuring.

• Largest customer accounts for less than 5% of sales.

Outlook and guidance

• Guidance for next year assumes flat USD exchange rates and 15% tariffs; any changes will impact results.

• Sales growth guidance is 10–14% (not currency adjusted); underlying growth estimated at 15–20% after currency effects.

• Expectation of significant EBITDA margin improvement as one-off restructuring costs are not recurring.

• Continued investment in automation and software, with CAPEX expected at $100 million for the coming year.

• Commercialization of the new sample management system targeted for 2026, pending customer feedback.